121 related articles for article (PubMed ID: 20718720)
21. Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology.
Einstein MH; Garcia FA; Mitchell AL; Day SP
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1185-9. PubMed ID: 21527581
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
23. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
24. HPV testing alone is not as safe as cytology and selective HPV testing: AGAINST: There is powerful evidence for primary cervical screening.
Kitchener H
BJOG; 2016 Jan; 123(1):68. PubMed ID: 26527427
[No Abstract] [Full Text] [Related]
25. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
[TBL] [Abstract][Full Text] [Related]
26. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.
Geraets DT; Heideman DA; de Koning MN; Snijders PJ; Meijer CJ; van Doorn LJ; Quint WG
J Clin Virol; 2009 Nov; 46 Suppl 3():S16-20. PubMed ID: 20129069
[TBL] [Abstract][Full Text] [Related]
27. HPV testing in primary screening of older women.
Cuzick J; Beverley E; Ho L; Terry G; Sapper H; Mielzynska I; Lorincz A; Chan WK; Krausz T; Soutter P
Br J Cancer; 1999 Oct; 81(3):554-8. PubMed ID: 10507785
[TBL] [Abstract][Full Text] [Related]
28. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and viral load of 51 genital human papillomavirus types and three subtypes.
Schmitt M; Depuydt C; Benoy I; Bogers J; Antoine J; Arbyn M; Pawlita M;
Int J Cancer; 2013 May; 132(10):2395-403. PubMed ID: 23034864
[TBL] [Abstract][Full Text] [Related]
30. A new PCR-based mass spectrometry system for high-risk HPV, part II: clinical trial.
Du H; Yi J; Wu R; Belinson SE; Qu X; Yang B; Wang C; Yi X; Belinson JL
Am J Clin Pathol; 2011 Dec; 136(6):920-3. PubMed ID: 22095378
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus detection in self-collected vaginal specimens and matched clinician-collected cervical specimens.
Khanna N; Mishra SI; Tian G; Tan MT; Arnold S; Lee C; Ramachandran S; Bell L; Baquet CR; Lorincz A
Int J Gynecol Cancer; 2007; 17(3):615-22. PubMed ID: 17504376
[TBL] [Abstract][Full Text] [Related]
32. Adoption of HPV testing as an adjunct to conventional cytology in cervical cancer screening in Japan.
Inoue M; Okamura M; Hashimoto S; Tango M; Ukita T
Int J Gynaecol Obstet; 2010 Nov; 111(2):110-4. PubMed ID: 20708184
[TBL] [Abstract][Full Text] [Related]
33. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture.
Schiffman MH; Kiviat NB; Burk RD; Shah KV; Daniel RW; Lewis R; Kuypers J; Manos MM; Scott DR; Sherman ME
J Clin Microbiol; 1995 Mar; 33(3):545-50. PubMed ID: 7751355
[TBL] [Abstract][Full Text] [Related]
34. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
Zhao J; Zhang X; Ma J; Liu G; Yao D; Zhang W; Wang J; Wei L; Zhao Y; Zeng Y; Liao Q
J Low Genit Tract Dis; 2012 Oct; 16(4):358-63. PubMed ID: 23023138
[TBL] [Abstract][Full Text] [Related]
35. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing.
Belinson JL; Du H; Yang B; Wu R; Belinson SE; Qu X; Pretorius RG; Yi X; Castle PE
Int J Cancer; 2012 Apr; 130(8):1855-60. PubMed ID: 21630255
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus screening in north Indian women.
Pandey S; Mishra M; Chandrawati
Asian Pac J Cancer Prev; 2012; 13(6):2643-6. PubMed ID: 22938435
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a new HPV genotyping assay based on next-generation sequencing.
Yi X; Zou J; Xu J; Liu T; Liu T; Hua S; Xi F; Nie X; Ye L; Luo Y; Xu L; Du H; Wu R; Yang L; Liu R; Yang B; Wang J; Belinson JL
Am J Clin Pathol; 2014 Jun; 141(6):796-804. PubMed ID: 24838323
[TBL] [Abstract][Full Text] [Related]
39. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
40. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
